Gamida Cell Adds David Fox to Board of Directors

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that David Fox has been appointed to Gamida Cell’s board of directors as an independent member. Mr. Fox brings significant leadership, company-building and business development experience to Gamida Cell’s board of directors as the company advances its clinical development candidates: omidubicel, an advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of bone marrow transplant, and GDA-201, an investigational, natural killer (NK) cell-based cancer immunotherapy in Phase 1 development in patients with non-Hodgkin lymphoma (NHL).

“We are pleased to welcome David to our Board of Directors,” stated Julian Adams, Ph.D., chief executive officer at Gamida Cell. “David has expertise fostering culture at growing, global organizations and executing strategic partnerships. His insights will be invaluable as we work to maximize the potential of our clinical programs and bring potentially curative cell therapies to patients.”

“I’m excited to join Gamida Cell’s board of directors,” said Mr. Fox. “Gamida Cell is at an exciting point in its trajectory. Recent Phase 3 data has demonstrated that omidubicel has the potential to provide a new standard of care in bone marrow transplant, and GDA-201 has demonstrated compelling clinical activity in patients with lymphoma. I look forward to working with Gamida Cell to achieve its goals as the company enters its next phase of growth.”

Mr. Fox was most recently a partner at Kirkland & Ellis LLP and served as a member of its Global Executive Management Committee. Mr. Fox is a director of Israel Discount Bank of New York, a member of the board of directors at the Park Avenue Armory, and on the board of governors and an honorary fellow of the Hebrew University, Jerusalem.

During May this year, Gamida Cell Ltd. raised $60 million to fund the launching of its first product omidubicel for the treatment of high-risk hematologic malignancies, as well as announcing positive Phase III results for Omnidubicel and it is confident that it will receive marketing approval for the treatment. The funds will be used for the continued clinical development of its product candidates, the expansion of its commercial manufacturing capabilities and general corporate purposes.

Gamida Cell‘s shareholders before the offering were: Novartis (13%), Access Medical (14%), Clal Biotechnology Industries Ltd. (TASE: CBI) (9%), Elbit Medical Technologies (TASE: EMTC) (8%) and Fidelity Fund (9%).

In the offering, Gamida Cell issued 13,333,334 ordinary shares at a public offering price of $4.50 per share. Gamida Cell has also granted the underwriters a 30-day option to purchase up to an additional 2,000,000 ordinary shares at the public offering price, less the underwriting discounts and commissions.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit https://www.gamida-cell.com.

About Omidubicel

Omidubicel (formerly known as NiCord®), the company’s lead clinical program, is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has also received Orphan Drug Designation in the U.S. and EU. In a Phase 1/2 clinical study, Omidubicel demonstrated rapid and durable time to engraftment and was generally well-tolerated.1 A Phase 3 study evaluating Omidubicel in patients with leukemia and lymphoma is ongoing in the U.S., Europe and Asia.2 Omidubicel is also being evaluated in a Phase 1/2 clinical study in patients with severe aplastic anemia.3 The aplastic anemia investigational new drug application is currently filed with the FDA under the brand name CordIn®, which is the same investigational development candidate as Omidubicel. For more information on clinical trials of Omidubicel, please visit www.clinicaltrials.gov.

Source: Businesswire

Show Buttons
Share On Facebook
Share On Twitter
Share On Linkedin
Hide Buttons